GOSS at a glance
Gossamer Bio, Inc. (GOSS, SEC CIK 1728117) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Gossamer Bio, Inc. (GOSS) shares worth $16.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $48.5M
- −57.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 23 funds
- $16.7M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $38.4M, up $25.1M YoY from $13.3M, driven by $37.1M contract-liability release
- Operating margin 18.7% vs (369.4)% YoY, reflecting operating income $7.2M vs loss $49.1M
- Seralutinib largest development program, R&D expense $18.2M vs $45.5M YoY
- Cash, cash equivalents and marketable securities $51.2M at September 30, 2026, funding operations into Q1 2027
- Operating cash use $107.7M, August private placement provided $25.0M, NDA acceptance and capital needs remain key uncertainties
Risk Factors
- Regulatory risk: PROSERA missed its primary endpoint, potentially prompting FDA rejection, added studies, or narrower seralutinib labeling
- Filing risk: FDA may refuse NDA filing despite September 2026 submission and favorable Pre-NDA meeting interpretation
- Liquidity risk: Missed NDA Acceptance Milestone could eliminate approximately $125.0 million Second Closing proceeds by December 31, 2026
- Financing risk: Purchase Agreement restrictions may limit additional equity fundraising if the Second Closing fails
- Development risk: Additional FDA-required studies could delay approval and increase seralutinib development costs
AI summary of the GOSS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- First NDA submitted for seralutinib in PAH, creating a major regulatory catalyst ahead of potential FDA filing acceptance and approval
- FDA acceptance could unlock up to approximately $125 million in additional committed capital, supporting potential 2027 commercialization
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders approved potential share issuance exceeding 20% of pre-closing shares under the August 20, 2026 Purchase Agreement
- Approval covers Pre-Funded Warrants, FDA Approval Warrants, and Series A-1, A-2, and A-3 Preferred Stock conversions
Item 8.01: Other Events
- Nasdaq minimum bid-price deficiency cured; continued listing on Nasdaq Global Select Market preserved
- Compliance followed 1-for-80 reverse stock split effective September 10, 2026
AI summaries of GOSS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for GOSS
Don't miss the next GOSS filing
- Alerts as it files. A push when GOSS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut GOSS, by share count.
- Ask anything. An AI agent that reads every GOSS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Cox Russell J. | A | Sep 23, 2026 | 10,000 | - |
| Daniel Thomas O | A | Sep 23, 2026 | 10,000 | - |
| Drynan Skye | A | Sep 23, 2026 | 10,000 | - |
| Milligan Sandra | A | Sep 23, 2026 | 10,000 | - |
| Ciongoli Gregory Austin | A | Sep 23, 2026 | 30,000 | - |
| Quisel John D | A | Sep 23, 2026 | 10,000 | - |
| Nathan Steven D | A | Sep 23, 2026 | 10,000 | - |
| Peterson Caryn | A | Aug 24, 2026 | 5,800,051 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $114.7M | $48.5M |
| Operating Income | - | -$59.9M | -$170.7M |
| Net Income | - | -$56.5M | -$170.4M |
| Op. Margin | - | -52.2% | -352.2% |
| Net Margin | - | -49.3% | -351.5% |
| Balance Sheet | |||
| Total Assets | - | $315.3M | $172.2M |
| Equity | $62.8M | $29.5M | -$122.8M |
| ROE | - | -191.7% | 138.8% |
| Per Share | |||
| EPS | $-1.18 | $-0.25 | $-0.75 |
| Cash Flow | |||
| Operating CF | -$159.2M | -$3.5M | -$171.3M |
| CapEx | $0 | $0 | $79K |
Source: XBRL data in Gossamer Bio, Inc. (GOSS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate GOSS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $16.7M |
| Q1 2026 | 23 | $18.7M |
| Q4 2025 | 24 | $192.2M |
| Q3 2025 | 23 | $139.4M |
| Q2 2025 | 24 | $53.3M |
| Q1 2025 | 17 | $29.2M |
| Q4 2024 | 11 | $23.3M |
- D.E. Shaw & Co+40.57M (+10418%)
- Renaissance Technologies LLC+10.41M (+855%)
- AQR Capital Management+5.50M (+54%)
- Two Sigma Investments+2.65M (+55%)
- Millennium Management+2.22M (+1182%)
- BlackRock−9.16M (-54%)
- State Street Corp−3.27M (-75%)
- Bank of America Corp−2.78M (-87%)
- Vanguard Portfolio Management LLC−1.62M (-75%)
- Northern Trust−950.5K (-67%)
- StoneX Group Inc.+27.6K
- Citizens Financial Group+13.5K
- T. Rowe Price Group−132.0K
- Principal Financial Group−17.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 145 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
GOSS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Oct 28, 2026 | - | Analysis | - |
| 8-K | Sep 28, 2026 | - | Analysis | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 8-K | Sep 16, 2026 | - | Analysis | - |
| 8-K | Sep 11, 2026 | - | Analysis | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Sep 3, 2026 | - | Analysis | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
GOSS SEC filings: frequently asked questions
Which institutions hold GOSS stock?
As of June 30, 2026, the largest Gossamer Bio, Inc. (GOSS) holders among the 13F filers tracked by SignalX were D.E. Shaw & Co ($6.7 million), AQR Capital Management ($2.6 million), Renaissance Technologies LLC ($1.9 million), Vanguard Capital Management LLC ($1.6 million), BlackRock ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was GOSS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75. The figures come from the XBRL data in the 10-K.
What did GOSS report in its latest 8-K?
Gossamer Bio, Inc. (GOSS) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest GOSS SEC filings?
Gossamer Bio, Inc. (GOSS) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 25, 2026.
What is GOSS's SEC CIK number?
Gossamer Bio, Inc. (GOSS)'s SEC Central Index Key (CIK) is 1728117. EDGAR lists every GOSS filing under that number.
Ask anything about GOSS
The research agent reads GOSS's filings, financials, insider trades and 13F holders, then answers with sources.